Replimune Group, Inc. REPL
Set alert
As of Nov 3, 12:08 PM ET
- YTD
- +104.53%
- 1 year
- +113.53%
- Open
- 19.52
- Prev close
- 19.49
- Mkt cap
- 1.88B
- Vol
- 2.28M
- Avg vol
- 2.95M
- EPS
- -2.79
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 19.50
- High
- 21.26
- Forward P/E
- -29.05
- Beta
- 0.93
- Short ratio
- 11.50
- Inst. own
- 105.25%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 2, 2027
- 50-d avg
- 13.58
- 200-d avg
- 9.29
- 1y target
- 23.33
1m chart
Built from the cached one-day intraday bars.
Signals (39)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Nov 3, 11:57 AM | 11 minutes ago |
| SMA: Bearish | Nov 3, 11:57 AM | 11 minutes ago |
| SMA: Bullish | Nov 3, 11:53 AM | 15 minutes ago |
| MACD: Buy Signal | Nov 3, 11:45 AM | 23 minutes ago |
| SMA: Bullish | Nov 3, 11:44 AM | 24 minutes ago |
| RSI: Oversold | Nov 3, 11:42 AM | 26 minutes ago |
| MACD: Sell Signal | Nov 3, 11:40 AM | 28 minutes ago |
| MACD: Buy Signal | Nov 3, 11:38 AM | 30 minutes ago |
| RSI: Oversold | Nov 3, 11:36 AM | 32 minutes ago |
| MACD: Sell Signal | Nov 3, 11:35 AM | 33 minutes ago |
| SMA: Bearish | Nov 3, 11:30 AM | 38 minutes ago |
| MACD: Buy Signal | Nov 3, 11:24 AM | 44 minutes ago |
| MACD: Sell Signal | Nov 3, 11:17 AM | 51 minutes ago |
| RSI: Oversold | Nov 3, 11:17 AM | 51 minutes ago |
| SMA: Bearish | Nov 3, 11:15 AM | 53 minutes ago |
| SMA: Bullish | Nov 3, 11:14 AM | 54 minutes ago |
| SMA: Bearish | Nov 3, 11:13 AM | 55 minutes ago |
| SMA: Bullish | Nov 3, 11:11 AM | 57 minutes ago |
| SMA: Bearish | Nov 3, 11:09 AM | 59 minutes ago |
| MACD: Buy Signal | Nov 3, 11:08 AM | 1 hour ago |
Newest 20 of 39.
Discussion (20)
Sign in to join the discussion
Mark REPL 2 months ago #1IOVA is king.
Mark REPL 3 months ago #2Sold and loaded the boat with IOVA shares. Good luck.
Mark REPL 3 months ago #3Wow that was close 10000 shares sold.
Mark REPL 3 months ago #4Sold the news leaked on Reddit.
Mark REPL 3 months ago #5Volume is low.. not good..
However, if Dr. Richard Pazdur returns to lead the FDA, the impact on Iovance Biotherapeutics (IOVA) is expected to be highly favorable, particularly for its long-term oncology pipeline.
A potential return of Dr. Richard Pazdur to the FDA is widely seen as bad news for REPL because he is historically the primary reason their melanoma drug was rejected.
$REPL @TILS KILLS CANCER ?? Today is Monday, dummy
$REPL ?? Oh SHIT! ? Its gonna take off
Today the Earnings Date for $REPL ???